Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3

Status

Completed 4Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 13Gastrointestinal 6Dermatologic 6Genitourinary 4Sarcoma 3Other neoplasm 3Tumor-Agnostic 1Thoracic 1Lymphoid 1Gynecologic 1Breast 1

Conditions

Adenomatous Polyposis Coli 3Colorectal Neoplasms 2Stomach Neoplasms 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colonic Polyps 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Eflornithine × Gastrointestinal × Clear all
NCT01349881 2026-04-02

PACES

SWOG Cancer Research Network

Phase 3 Active not recruiting
354 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02794428 2024-10-16

Chemoprevention of Gastric Carcinogenesis

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
91 enrolled 10 charts
Gastrointestinal

Gastritis, Atrophic, Stomach Neoplasms

NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT01245816 2015-04-24

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Withdrawn
Gastrointestinal

Colonic Polyps, Adenomatous Polyposis Coli

NCT00003076 2012-12-19

Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus

University of Michigan Rogel Cancer Center

Phase 2 Completed
152 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡